The largest issuer and distributor in South Korea accumulated KRW253.4 billion (US$2.3 billion) from OTC derivatives in 2020 on the back of its activity in the second half of the year, up 73% from 2019.
OTC derivatives, which consist of equity-linked securities (ELS) and derivative-linked securities (DLS), derived revenues of KRW52 billion, KRW26 billion, KRW102 billion and KRW73.3 billion throughout the four quarters in 2020, respectively. Together they represented 74.2% of the firm’s financial products sales. In terms of assets under management, OTC derivatives rose to KRW3.5 trillion in Q4 20 from KRW3.4 trillion quarter on quarter (QoQ), or from KRW3.3 trillion a year ago. In
Continue reading with a subscription to the SRP market intelligence platform.
Request DemoAlready a subscriber? Login